The sensitivity for diagnosing pancreatic cancer and CRC is ~70 and 45%, respectively, and the specificity is ~95 and 83%, respectively.244–246 As CA242 exhibits a lower sensitivity for diagnosing pancreatic cancer, the combination of CA242 with CEA is a promising strategy for improving diagnosis sensitivity in pancreatic cancer.247 In addition, CA242 is also used as a clinical indicator of progression or recurrence during chemotherapy for pancreatic cancer.241,242. This evidence concerns the gene CEACAM5 and familial pancreatic carcinoma.